Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
{When everything seems to be going against you, remember that the airplane takes off against the wind, not with it.}
… Great analogy
- When they get approval, IMO, it’ll take off
Thanks for sharing :)
I know at one point they were hiring a new person to handle emails etc … let’s just hope the tests come back soon and they can get the fda the needed information…
That’s frustrating
Perhaps email them with this suggestion.. honestly, it couldn’t hurt … they aren’t a PE firm they are scientists … research and development of medicine is a far different animal than Twitter pr … they’ve shown they are receptive to constructive feedback as shown this summer with the rs debacle. This company has huge potential with the patent :)
Email reply from QNTA I expressed I’m patiently waiting for news, however many on iHub are getting (justifiably) restless .. I inquired if there was any news yet .. here’s a quote directly from QNTA
[“We are waiting patiently on our end as well to deliver some news that would brighten everyone's spirits.”]
… this is why no pr from them as it’s silly if they push out “still waiting” … I have faith in the science and have worked with enough government agencies to know “hurry up and wait” is a common theme
GLTA
They are waiting on the additional test the fda now requires … this is a 500 thousand dollar mice dna test … which they hadn’t anticipated- no one did - not even the fda - this is a NEW test requirement added into the whole picture as because of the mRNA covid shots they NOW want to know how drugs affect humans on a dna level … sooooo qnta obliged and is now waiting - like all of us - for those results to in turn give them to the fda …. Personally the most troubling part of this whole paragraph is “because of the covid shots they now want to know how drugs affect people on a dna level”…. Does no one else wonder what in the world are the covid shots potentially doing to the dna that now the fda required this???
…. The big unfortunate mess is this is taking longer than anyone planned…
I believe still we will get the approval once tests are completed and submitted …
I have no plans to sell a single share anytime soon.
Polarization technology patent $cience
https://medoliferx.com/
They are Quiet because they too are waiting ..
It seems folks are impatient and want information but get mad at fluff PRs … hard to put out a PR when they are waiting on the ticker change & waiting on fda … I’m quite sure they’d love nothing more than to be giving us forward statements…
WHEN news is available it’s shared - lest not forget about the exciting news of the Advil increased efficacy!! The polarization technology was used in the muscle rub as proof of concept then verified through the Advil testing!! This alone was outstanding - and was very recent news :) … thus far all things talked about on the CCs has occurred or is in process …. Waiting isn’t fun for anyone … however, when I’m frustrated waiting I read all the science, data, look at patents and hear the CCs… when disparaged I get re-exhilarated by the information at hand -step back and look at the big picture … future is bright :)
UNFORTUNATELY they had bad advice this summer about placing a RS into their filings … this rightfully set off alarm bells for many of us .. the GLORIOUS TURN OF EVENTS was THEY LISTENED to Share Holders and subsequently REMOVED RS. This too is an incredibly important piece of information to this puzzle - this means they are willing to listen learn and implement in order to improve … one has to make the leap that employees of QNTA are also fellow share holders - I’m confident they want to see this company succeed as much or more than any of us … remember escozine research is now ongoing for decades … today for those new to qnta we are all witness to the precipice of the culmination of mergers and products proof of concept and fda push stage of this … this stock isn’t a flip it’s a company of science that I’m super excited to be invested in, and we are the way I see it coming up to a huge pinnacle …
Slow and steady wins the race … we can commiserate on iHub and Monday morning quarterback Orrrrr we can utilize our ability to email constructive helpful analysis and or queries to qnta directly.. and also we can help by buying and promoting the products ourselves … as folks when seeing the efficacy of the products and upon reading / learning about the science they can not only become customers of buying product but even better yet will get excited about the stock … as a share holder I’m optimistic and want to see success for all of us AND I want the people on this planet given access to medicines that through polarization technology can be given in smaller less harmful doses with great efficacy… polarization technology patent $$ $ It’s No secret here - I’m long with this
GLTA $cience QNTA MedolifeRx AELIA
Have a great weekend, order some imunapen & muscle rub if you haven’t already … or any of the products they have at the AELIA store :)
https://aeliastore.com/
https://ir.quantrx.com/news-events
Escozine is in the process of getting FDA approval… the company is doing EXACTLY what was asked of them .. fda said because of covid vaccine they NOW REQUIRE testing on a dna level the effects of drugs … which, this additional test asked of them costs $500,000.oo to perform … soooo qnta is having that test done currently and we should hear results in the coming weeks (??? End of December maybe ?? Who knows - seemingly EVERY aspect of life on planet earth is taking exponentially longer since covid befell our planet). I digress … keep in mind that the muscle rub was created NOT as QNTA product for revenue as much as instead, if you read what’s been written by the company mgmt / scientists etc .. you’ll see the muscle rub was created in order to show “proof of concept” for the effectiveness of their patented polarization technology… which, the company has very recently shown how this polarization can be utilized for things like Advil …
Qnta, at this juncture, is doing exactly as they indicated they were doing …
QNTA is an investment in escozine (very recently given a huge nod from the DR), investment in the scorpion ranch that’s being built up now, investment in their patented polarization technology, investment in $cience ….
While it’s easy to arm chair Monday morning quarterback qnta … if one steps back and connects the dots this small but very innovative company is putting together … IMO this is a long hold and a company that’s science has the exponential potential to have positive far reaching revenue streams
Decades of research … we can certainly be patient as we close in on the testing data that’s been asked for …
Paytience ;~}
This song is rattling around in my head today … while we wait for ticker change and for the mice test results … the song in my head on a loop right now lol
… “It’s gonna take paytience and time”
[{“The Company hopes to soon receive approval on their name and symbol change, which was announced earlier this year.”}] https://ir.quantrx.com/news-events/press-releases/detail/95/medolife-rx-announces-upcoming-release-of-new-aelia
Medolife Rx Announces Upcoming Release of New Aelia Commercials Featuring Tony Hawk
https://ir.quantrx.com/news-events/press-releases/detail/95/medolife-rx-announces-upcoming-release-of-new-aelia
You might want to consult a magic 8 ball
While we all continue to wait ~ here’s a Hilarious paint drying story distraction
“ Why Someone Made a 10 Hour Film of Paint Drying “
Enjoy ;~} (insert chuckle here)
Cue the music … jeopardy theme song
lol ;~} annnnnd we wait qnta Will have it’s day soon enough
Yes. They did … it’s nothing noteworthy
Like ive said before … slow and steady
They are getting things done
[{“We are indeed still waiting on FINRA for the name and symbol change. We will update everyone as soon as we get an update.”}] : I received this just now,TODAY, from qnta after I emailed and inquired. So no worries from me.
QNTA escozine MedolifeRx AELIA
My take / mantra .. Slow and steady wins the race … they (QNTA MedolifeRx are and have been doing all the things they’ve indicated they would … some times things just take longer than we’d like … paytience is my game plan … as the $cience / data / research / patent / scorpions / escozine are all there … the company is just having to jump through the preverbal hoops as they align everything)
https://aeliastore.com/
Holidays fast approaching…
Hanukkah’s early this year starting
On Sunday, November 28
And Christmas is just 6.5 short weeks away … Santa’s helpers may enjoy some muscle rub in their stockings
.. if they are on the nice list that is ;)
MedolifeRx QNTA $cience AELIA
it’s all on track and proceeding as they indicated it would $ $ $
https://aeliastore.com/
https://ir.quantrx.com/news-events/press-releases/detail/94/medolife-rx-announces-uplisting-to-otcqb-venture-market
$cience QNTA
GLTA
TheLittle Blue $corpion (engine) that could
QNTA $cience MedolifeRx Escozine AELIA
Great news today!
Things are falling into place as indicated they would GLTA
$cience QNTA MedolifeRx AELIA escozine Polarization tech patent
… Tests take time …. We are all just patiently biding our time …
Happy November iHub folks
GLTA
I’d say thats reasonable
$cience … things take time
Testing over seas will eventually conclude and the fda will subsequently get their asked for data … (recall, the data set was extra tests NOW added by the fda because of covid vaccines … dna test effects etc on mice ). In the mean time we wait … decades of research we can’t get impatient over a few seemingly long months …
Happy Halloween everyone be safe and have fun :)
Polarization technology patent is where the money is … also worth noting, escozine was initially being put through the FDA as an orphan drug for cancer uses it only got switched over to a Covid drug in order to get it through the FDA process quicker .. the company has much to offer .. Covid is not the catalyst that will drive this company to great successes instead it’s the science the patent scorpion venom research imunapen and more skus to follow … escozine cancer research
AELIA escozine MedolifeRx QNTA
Ps covid sadly isn’t going anywhere.. the beautiful thing about the scorpion ranch expansion is it will allow the escozine to be mass produced and subsequently price per unit will come down - escozine is now been adopted by the DR to use with their covid protocol… other Latin countries surely will follow …. Many countries are utilizing OTHER solutions to combat civid besides relying on vaccines … speaking of vaccine it’s worth also noting escozine has been shown when used along with receipt of vaccine to reduce side affects
$cience QNTA $$$$ I’m in this one for the long haul. GLTA
Like the story of the little engine that could
QNTA $cience
…. Choo choo $ $ $
IMO that is ;~)
Good morning all
For those who don’t have this link
You can sign up to get direct emails;
https://ir.quantrx.com/news-events/email-alerts
“ Email Alerts. Sign up for email alerts for Press Releases & SEC Filings”
https://ir.quantrx.com/
[{“Subsequent to the acknowledgement of the trial, the FDA has requested that the Company complete two additional toxicology studies in animals. Since adoption of COVID-19 vaccinations, the FDA altered its protocol for measuring toxicology to include studying it at the DNA level. As this is a newer development, the agency has asked Medolife to provide data in this regard. Medolife has the product and protocol necessary to complete these studies in short-order.
“We could not be more pleased with the response from the FDA, in its acknowledgment of our clinical trials on Escozine and its potential therapeutic benefit, as well as the very clear guidelines set forth in the response for moving our program forward,” said Medolife CEO Dr. Arthur Mikaelian.
The acknowledgment by the FDA of the clinical trial conducted in the DR as a proof-of-concept for Escozine®’s therapeutic potential as a COVID-19 therapeutic is an important aspect of the response.]}
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210623:nGNEb85TRd&default-theme=true
QNTA MedolifeRx AELIA $cience Escozine
https://aeliastore.com/
Fdc4 - well stated. QNTA $cience
The ceo is a scientist … investors here should focus on the science, data, patents and products. While Arthur Mikaelian may not be flashy like a television actor - he’s calm pragmatic and well versed in the $CIENCE. The money here will come from the patented polarization technology (read up on the Advil study - amazing the increased efficacy with smaller doses), money will come from escozine garnering recently being given the go ahead in the DR to be used for covid protocol, the money will come when escozine gets fda approval, … the money will come
In the mean time … waiting is boring
Listening to data can sound boring .. but when you listen to the data, and combine that with the potential uses (Advil was just a test - imagine chemo drugs more effective in less quantity? That equates to patients suffering less ) … the big picture is it’s all culminating together …. The Aelia products are great and will serve as a revenue stream - but part of the big picture is the Aelia products show proof of concept that the polarization technology not only works it works well!!!
Imunapen is huge as well.
I suggest to all give the products a try … have patience for the fda and ticker change … but ultimately, decades of research is on the precipice of being $$$
Qnta MedolifeRx Aelia escozine
Paytience .. things are coming together;
[{ “Beyond the opportunity for us to help the population of the DR, an approval of this kind will open the door to further negotiations for distribution in other Latin American countries.”
“ (in the DR) “….. allowing for rapid distribution of Escozine® throughout the country.” }]
Excepts quoted from the following:
https://ir.quantrx.com/news-events/press-releases/detail/93/medolife-rx-announces-that-the-government-of-the-dominican
Press Releases
Medolife Rx Announces that the Government of the Dominican Republic is Willing to Include Escozine into its COVID-19 Treatment Regimen
Download as PDF OCTOBER 14, 2021 8:30AM EDT
BURBANK, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that its CEO, Dr Arthur Mikaelian, had a successful meeting with the Vice President of the Dominican Republic (DR), Raquel Peña de Antuña, where the official expressed interest in introducing Escozine® into the government’s COVID-19 program after reviewing results from the Company’s study.
In an in-person meeting, which took place at government facility in Santo Domingo on 10/13/21, the Company presented findings from its study on the effects of Escozine on 450 patients who had tested positive for COVID-19. After reviewing the findings, the Vice President of the DR, who has been tasked with overseeing the COVID-19 response by the government of the DR, expressed appreciation for the support of the country by Medolife and her belief in the importance of Escozine for the country. Further, she shared that she would be supportive of immediately forming a government committee in the DR that would expedite the processing of the product, allowing for rapid distribution of Escozine® throughout the country. A committee could be organized as quickly as within a week. Beyond the distribution of Escozine® throughout the DR, the Vice President also expressed a strong desire to solidify an agreement to introduce the benefits and effectiveness of Escozine® as a COVID-19 therapy to other countries. Finally, the VP shared that she will look to make plans to visit the Company’s first-of-its-kind scorpion reservation and manufacturing facility.
“This creates an opportunity for Medolife to demonstrate Escozine’s effectiveness in the country as a therapeutic and palliative medicine,” said Medolife CEO Dr. Arthur Mikaelian. “Through our study on Escozine®, we were able to show that it diminishes some of the side-effects of vaccines. This creates more confidence by the general population and further aids governments in implementation of vaccine programs. Beyond the opportunity for us to help the population of the DR, an approval of this kind will open the door to further negotiations for distribution in other Latin American countries. Overall, the outcome of the meeting was very positive, and we look forward to working closer with the Vice President and government of the DR.”
Medolife’s CEO also shared details of some of the other products that Company produces such as its line of Immunapens, which are formulated into four effects-based products: energy and focus, stress relief, sleep aid, and general immune support. The government official shared additional enthusiasm for those products and her interest in their distribution as well. Mikaelian also discussed how the Company could assist in the financial applications of such a large Escozine® distribution through philanthropic initiatives that positively support larger health-related needs of the government healthcare system.
The COVID-19 pandemic has continued to wreak havoc on state healthcare systems globally, adding additional pressure than in normal circumstances. While cases continued to be monitored closely, the Company and the government will work together to prepare for any additional waves of infection rates, through the introduction of Escozine® and promotion of vaccines.
This agreement by the government of the DR to distribute Escozine® creates an opportunity for Medolife to generate revenues on its lead drug candidate, while simultaneously completing the US FDA requirements for product approval in the United States.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness and nutraceutical products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian’s polarization technology which applies advances in quantum biology to increase the potency of active ingredients. Currently, QuantRx supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
ir@medoliferx.com
Source: Quanta, Inc.
Released October 14, 2021
…. all in due time
lot of things all culminating together …
“good things come to those who wait”
https://aeliastore.com/
QNTA MedolifeRx AELIA escozine Polarization patent $cience $corpion
Exactly. Know what you own
I agree penny world
I’m holding long term QNTA $$$
The data is sound …
fda and testing takes time
Paytience pays QNTA
In my opinion, the years of research are culminating together and moving in the right direction in order to get escozine approved in proper fashion - not only with the fda / US but also abroad.
In regards to polarization technology, Proof of concept of the polarization technology was kept under the radar purposefully by quietly rolling out the Aelia muscle rub in order to be able to show the increased potency / efficacy of a product of which the polarization technology was used to produce said product. Now with proof of concept in hand and in the market place, add in the latest data showing significant increase in Advil potency, they have a solid data set to bring to companies showing how and why their technology could be utilized by other companies.
I suggest to all longs and new investors to go back and relisten to Conference calls and peruse the DD ..
Here’s an article showing the arduous process of new drugs … it takes a long time from start to the finish line … it’s been years already … while it’s seemingly feeling like an eternity … a few months in the grand scheme of things is negligible..
I’m long, and have added more ..
GLTA QNTA $$
https://www.drugs.com/fda-approval-process.html
Holidays are around the corner - I’m ordering Halloween treats (AELIA products ) for a few friends who’ve had too many tricks this October.. the plan is to treat them with pain relief :)
As investors it behooves us to purchase AELIA products, use them and subsequently also great idea to send to folks we KNOW could benefit from them
https://aeliastore.com/
… it’ll be like the 80s hair product commercial “and they told two friends & they told two friends & so on” ;~)
Pain relief is a huge deal!!! When folks find a remedy that truly works they literally tell EVERYONE they know … being in pain is beyond miserable. It’s literally a miraculous feeling when pain is relived
Good morning iHub :)
Greeeeen :~$) QNTA
$ MedolifeRx $ AELIA $ escozine $ QNTA $ polarization technology $ patent $cience $
Right??!!! It’s a Refreshing sight!!!
We all KNOW all the reasons why it SHOULD be going up, the potential is all there : patents, science, data, scorpion venom, escozine, muscle rub, imunapen, research, polarization technology, skin care products, therapeutics …. $$$$
$$$ QNTA $$$
Market strategy should be : escozine has been proven helpful When PAIRED WITH receiving Vaccine …. The government seems keen to stranglehold citizens with vaccine mandates … HOWEVER side affects aren’t fables … using this Angle takes focus away and off use of escozine as a stand alone therapeutic …
~~~~~~~~~~
“Physicians observed that patients who originally had strong adverse reactions
to COVID-19 vaccines and who were given Escozine®, experienced significantly
lessened side effects. Typical vaccine side effects are similar to symptoms of
the actual COVID-19 virus, including body cough, aches, fatigue and fever,
among others.”
https://www.bloomberg.com/press-releases/2021-07-08/quanta-inc-medolife-rx-clinical-observations-demonstrates-effectiveness-of-escozine-in-complementary-use-with-covid-19
Great find MulaGreen,
… it’s truly scary to see the harmful side affects that some are unfortunate to be experiencing and yet the refusal of some to admit that it is of and should be of great concern… purity levels in this article are troubling …
I hope escozine continues gaining traction and is acknowledged by not only the fda but subsequently then governments abroad as well.. id love to see dolling out of therapeutics also as opposed to solely seemingly pushing vaccines ….
With So much shouting about “follow the science” in the news these days … it’s worth noting QNTA has just that; SCIENCE and lots of quantified subsequent data and trials to back it up.
$$$ QNTA MedolifeRx AELIA escozine